Plasminogen (medication)
| Plasminogen (medication) | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Plasminogen is a medication used in the treatment of certain medical conditions related to fibrinolysis. It is a precursor to plasmin, an important enzyme that breaks down fibrin clots. This medication is primarily used in the management of hypoplasminogenemia, a rare condition characterized by low levels of plasminogen in the blood.
Mechanism of Action[edit]
Plasminogen is converted into its active form, plasmin, by tissue plasminogen activator (tPA) or urokinase. Plasmin then degrades fibrin, a key component of blood clots, into soluble fragments. This process is crucial for the maintenance of normal blood flow and prevention of thrombosis.
Indications[edit]
Plasminogen is indicated for use in patients with congenital plasminogen deficiency, which can lead to the development of ligneous conjunctivitis, a condition characterized by the formation of wood-like pseudomembranes on the conjunctiva.
Administration[edit]
Plasminogen is administered via intravenous infusion. The dosage and frequency depend on the severity of the deficiency and the clinical response of the patient.
Side Effects[edit]
Common side effects of plasminogen therapy may include allergic reactions, fever, and headache. Serious side effects are rare but can include anaphylaxis and thrombosis.
Contraindications[edit]
Plasminogen should not be used in patients with known hypersensitivity to the drug or any of its components. It is also contraindicated in patients with active bleeding disorders.
See Also[edit]
References[edit]
